Last updated: November 8, 2026
Teflaro, the brand name for ceftaroline fosamil, is an intravenous cephalosporin antibiotic approved by the U.S. Food and Drug Administration in 2010 for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia. Its commercial trajectory has been shaped by hospital-only use, competition from established broad-spectrum antibiotics, limited resistance-driven differentiation, and the loss of meaningful U.S. exclusivity.
Teflaro generated modest commercial revenue relative to major pharmaceutical products. Forest Laboratories launched the drug, Actavis acquired Forest in 2014, Allergan acquired Actavis in 2015, and AbbVie acquired Allergan in 2020. Teflaro is not a material standalone revenue driver in AbbVie's public financial reporting.
What is Teflaro and how is ceftaroline fosamil used?
Teflaro is an injectable prodrug that converts to ceftaroline, a beta-lactam antibiotic with activity against methicillin-resistant Staphylococcus aureus, or MRSA, and selected gram-positive and gram-negative pathogens.
The FDA-approved indications are:
| Attribute |
Teflaro |
| Active ingredient |
Ceftaroline fosamil |
| Dosage form |
Intravenous injection |
| Drug class |
Fifth-generation cephalosporin |
| Initial U.S. approval |
October 29, 2010 |
| Original indications |
Acute bacterial skin and skin-structure infections; community-acquired bacterial pneumonia |
| Primary commercial setting |
Hospital and institutional care |
| Manufacturer history |
Forest Laboratories, Actavis, Allergan, AbbVie |
| Administration |
Intravenous infusion |
| Main clinical differentiator |
Activity against MRSA with beta-lactam characteristics |
Teflaro is not an oral product. Its injectable-only status limits outpatient convenience and narrows the addressable market compared with oral antibiotics and long-acting formulations.
The FDA later approved a pediatric indication for patients from two months of age through less than 18 years of age in 2015. Pediatric labeling changes extended regulatory exclusivity but did not create a new large commercial market. (FDA, 2010, 2015)
How did Teflaro sales develop after launch?
Teflaro's commercial uptake was gradual and remained limited. Forest Laboratories reported product revenue in its annual filings, but later corporate owners generally did not disclose Teflaro as a separate material product line.
Public filings indicate the following commercial pattern:
| Period |
Commercial development |
| 2010 |
U.S. launch after FDA approval |
| 2011-2012 |
Early hospital adoption and formulary expansion |
| 2013-2014 |
Continued sales growth, but from a small base |
| 2014 |
Forest acquired by Actavis |
| 2015 |
Pediatric indication approved; Allergan acquired Actavis |
| 2016-2019 |
Mature, specialized hospital antibiotic product |
| 2020 onward |
AbbVie ownership following Allergan acquisition; no separate material revenue disclosure |
Teflaro did not achieve blockbuster scale. The product competed in a crowded inpatient antibiotic market that included vancomycin, linezolid, daptomycin, ceftaroline alternatives, and broad-spectrum beta-lactams.
Forest's filings reported Teflaro net sales in the tens of millions of dollars rather than hundreds of millions or billions. The product's financial contribution was therefore strategically useful as part of Forest's hospital portfolio but not large enough to remain a prominent standalone asset after successive acquisitions. (Forest Laboratories, 2013, 2014)
What drove Teflaro's market dynamics?
Hospital formulary positioning
Teflaro's principal commercial opportunity was inpatient treatment where physicians needed MRSA coverage and an alternative to vancomycin or other agents. Hospital purchasing decisions are controlled by antimicrobial stewardship committees, formularies, local resistance patterns, clinical pathways, and pharmacy budgets.
This structure restricts promotional leverage. A hospital may keep Teflaro available for selected cases without using it as a first-line product.
MRSA activity
Ceftaroline's MRSA activity gave Teflaro a useful clinical position. The product offered beta-lactam pharmacology in a setting where MRSA frequently requires nontraditional therapies.
Its differentiation was limited by competing drugs with established use, including:
- Vancomycin, which remained a default MRSA treatment.
- Linezolid, which offered oral and intravenous formulations.
- Daptomycin, which had established use in serious gram-positive infections.
- Ceftobiprole in markets where it was approved.
- Newer long-acting agents such as dalbavancin and oritavancin for selected skin infections.
Intravenous-only delivery
The absence of an oral formulation limits Teflaro's use for step-down therapy and outpatient treatment. Hospitals may prefer an oral agent when patients stabilize, reducing length of stay and pharmacy cost.
Antimicrobial stewardship
Stewardship programs often reserve broad-spectrum or advanced antibiotics for documented or strongly suspected resistant infections. That protects the clinical utility of Teflaro but limits routine volume.
Resistance and susceptibility
Ceftaroline is not a universal solution for resistant bacterial infections. It is not active against all clinically important pathogens, and susceptibility testing remains relevant. Resistance can emerge during therapy, particularly in severe infections with high bacterial burden or prolonged exposure.
When did Teflaro lose U.S. regulatory exclusivity?
Teflaro received five years of new chemical entity exclusivity beginning on October 29, 2010. That period expired in 2015. The pediatric exclusivity extension added six months after completion of qualifying pediatric studies, extending certain FDA protections into 2016. (FDA, 2010, 2015)
The regulatory exclusivity timeline was:
| Event |
Date |
| FDA approval |
October 29, 2010 |
| Five-year NCE exclusivity |
Through October 2015 |
| Pediatric indication |
2015 |
| Six-month pediatric extension |
Applied to eligible protections through approximately April 2016 |
Regulatory exclusivity and patent protection are separate. The end of NCE exclusivity did not automatically permit immediate generic marketing if enforceable patents remained listed or if litigation delayed approval.
What patents protect Teflaro and ceftaroline fosamil?
Teflaro's patent estate has included patents directed to cephalosporin compounds, pharmaceutical compositions, salts or prodrug forms, and methods of treatment. The commercially relevant protection has historically been narrower than the broad patent portfolios associated with biologics or complex delivery systems.
Public patent information associated with ceftaroline includes early Forest-related cephalosporin patent filings and later patents covering specific pharmaceutical forms and use claims. Patent scope and expiry depend on the exact patent, terminal disclaimers, patent-term adjustment, pediatric extensions, and Orange Book status.
The commercially important patent categories are:
| Patent category |
Potential protection |
| Compound patents |
Ceftaroline or related cephalosporin chemical structures |
| Prodrug patents |
Ceftaroline fosamil and conversion to active ceftaroline |
| Composition patents |
Injectable pharmaceutical compositions |
| Manufacturing patents |
Processes for producing active ingredient or drug substance |
| Method-of-use patents |
Treatment of bacterial infections or specific patient populations |
| Formulation patents |
Stable injectable preparations, salts, solvents, or excipients |
The earliest compound protection was not sufficient to support a long post-launch monopoly because the product launched in 2010 after years of prior patent development. Patent-term erosion reduced the effective commercial life.
What is the Orange Book status of Teflaro?
The FDA Orange Book is the controlling source for current listed patents and certification status. Teflaro's Orange Book relevance is limited by the product's age, its injectable dosage form, and the loss of original regulatory exclusivity.
For generic applicants, the key pathways are:
- Paragraph III certification, stating that listed patents will not be infringed or have expired.
- Paragraph IV certification, asserting that a listed patent is invalid, unenforceable, or will not be infringed.
- Section viii statement, omitting a patented method of use where the approved label permits a noninfringing use.
An injectable generic applicant may also pursue a 505(b)(2) application if it relies partly on existing literature or seeks differences from the reference product. The applicable pathway depends on the proposed formulation, labeling, manufacturing process, and listed patents.
Have companies challenged Teflaro patents under Paragraph IV?
No high-profile, commercially significant Paragraph IV dispute involving Teflaro has become a major public litigation event comparable with challenges to high-revenue small-molecule medicines.
That does not eliminate generic risk. A generic company can avoid litigation by filing after relevant patents expire, using a certification strategy that does not trigger litigation, or settling before a case produces a published judgment.
The relatively small market reduces the expected value of prolonged patent litigation. Generic companies are more likely to prioritize products with larger unit volumes or higher reimbursement unless manufacturing complexity limits competition.
What generic entry risks exist for Teflaro?
Generic entry risk is high from a commercial perspective because:
- The core U.S. regulatory exclusivity period has expired.
- Teflaro is a small-molecule injectable.
- Hospital buyers generally accept therapeutically equivalent generic antibiotics.
- The product lacks a large consumer brand franchise.
- AbbVie's public reporting does not identify Teflaro as a material protected-growth product.
Generic competition may still develop slowly if demand is low, manufacturing is difficult, or the active pharmaceutical ingredient has limited supplier capacity. Injectable antibiotics require compliance with sterile manufacturing standards, validated aseptic processing, container-closure controls, and reliable supply. Those requirements can delay or limit entry without preserving strong branded pricing.
What manufacturing and intellectual-property barriers affect Teflaro?
The principal barriers are technical rather than brand-based.
Sterile injectable production
Ceftaroline fosamil is supplied as an intravenous product. A generic manufacturer must demonstrate control over:
- Drug-substance synthesis.
- Prodrug purity and degradation products.
- Sterile filtration or aseptic processing.
- Lyophilization or powder characteristics where applicable.
- Reconstitution performance.
- Container-closure integrity.
- Stability under labeled storage conditions.
These barriers can reduce the number of suppliers, but they do not generally create durable exclusivity comparable with biologic manufacturing platforms.
Drug-substance supply
Reliable access to qualified ceftaroline fosamil drug substance is commercially important. A sponsor may face development delays if it relies on a limited number of qualified suppliers or must build an internal process.
Patent manufacturing claims
Process patents can create targeted obstacles even after compound patents expire. Their value depends on whether the generic can use a different process without infringing and whether the process claims remain enforceable.
How does Teflaro compare with competing hospital antibiotics?
| Product |
Main strength |
Commercial limitation versus Teflaro |
| Teflaro |
MRSA activity with cephalosporin class profile |
IV-only; lower market scale |
| Vancomycin |
Low cost and extensive clinical familiarity |
Monitoring burden; toxicity concerns |
| Linezolid |
Oral and IV administration |
Hematologic and drug-interaction concerns |
| Daptomycin |
Established serious gram-positive use |
Not indicated for pneumonia |
| Dalbavancin |
Long-acting dosing |
High acquisition cost; narrower use |
| Oritavancin |
Long-acting dosing |
Limited routine utilization |
| Ceftobiprole |
Broad advanced cephalosporin profile in approved markets |
Geographic availability varies |
Teflaro's strongest position is in selected hospitalized patients with suspected or confirmed MRSA infection where a beta-lactam option is clinically attractive. Its weakest position is routine empiric treatment where low-cost generic antibiotics dominate.
What is the competitive landscape for Teflaro?
Teflaro competes across three segments:
Traditional generics
Vancomycin and other generic intravenous antibiotics exert the strongest price pressure. Their low acquisition cost makes substitution difficult to overcome.
Branded advanced antibiotics
Daptomycin, linezolid in some settings, dalbavancin, and oritavancin compete for cases involving resistant gram-positive organisms. These products compete on dosing, tolerability, discharge efficiency, and institutional protocols.
New antibiotic development
New products targeting resistant pathogens can reduce the strategic value of Teflaro if they offer simpler administration, broader pathogen coverage, or better outpatient economics.
The market is therefore clinically segmented rather than controlled by a single direct substitute. Teflaro retains utility, but its price and volume potential are constrained.
What is Teflaro's current revenue exposure for AbbVie?
Teflaro is not identified as a major standalone revenue contributor in AbbVie's principal product disclosures. AbbVie's material revenue exposure is concentrated in products such as Humira, Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, and other large franchises.
Teflaro's economic importance is better characterized as:
| Financial factor |
Assessment |
| Standalone revenue scale |
Small relative to AbbVie |
| Growth potential |
Limited |
| Pricing power |
Moderate to low |
| Generic erosion risk |
High |
| Strategic value |
Portfolio continuity and hospital presence |
| Investor materiality |
Low unless supply, litigation, or divestiture issues arise |
The product is unlikely to materially affect AbbVie's consolidated earnings. Its commercial value may be higher to a specialty-antibiotic or hospital-products company than to a diversified pharmaceutical manufacturer.
What licensing deals and ownership changes affected Teflaro?
Teflaro originated within Forest Laboratories. Its ownership changed through corporate transactions rather than a widely disclosed standalone licensing transaction:
- Forest Laboratories developed and commercialized Teflaro.
- Actavis acquired Forest in 2014.
- Allergan acquired Actavis in 2015.
- AbbVie acquired Allergan in 2020.
These transactions transferred Teflaro's rights within broader corporate portfolios. Public disclosures have not established a major independent licensing deal that materially changed Teflaro's market outlook.
What litigation status affects Teflaro?
Teflaro does not have a widely reported current patent dispute that creates a major near-term market event. The relevant legal risks are generic certification, patent validity, Orange Book listing accuracy, manufacturing-process claims, and product liability.
Because the product is an older injectable antibiotic with modest revenue, litigation economics favor limited-duration disputes or nonlitigation entry strategies. Any future case would need to be evaluated against the specific asserted patent, proposed generic formulation, certification date, and potential 30-month stay.
What are the most likely generic launch scenarios for Teflaro?
Scenario 1: Gradual generic entry
One or more suppliers enter after patent clearance. Hospital contracts shift toward lower-cost alternatives, while branded Teflaro remains available for institutions with established protocols.
Scenario 2: Limited generic supply
Technical manufacturing requirements restrict the number of approved suppliers. Prices decline, but supply remains concentrated and shortages become a greater risk.
Scenario 3: Brand persistence without premium growth
Teflaro remains commercially available because some hospitals prefer the reference product, but volume and pricing remain constrained. This is the most plausible outcome for a mature hospital injectable without major new indications.
Key Takeaways
- Teflaro is an intravenous ceftaroline fosamil antibiotic approved in 2010.
- Its commercial differentiation is MRSA activity within a cephalosporin framework.
- Sales remained in the tens-of-millions range rather than reaching blockbuster scale.
- Forest Laboratories launched the product; ownership later moved to Actavis, Allergan, and AbbVie.
- U.S. NCE exclusivity expired in 2015, with pediatric extension benefits reaching into 2016.
- Generic-entry risk is high because Teflaro is an older small-molecule injectable with no major current regulatory exclusivity.
- Sterile manufacturing and drug-substance supply can slow entry but are not equivalent to durable patent protection.
- Teflaro is unlikely to be financially material to AbbVie.
- The product's commercial future depends more on hospital formularies, supply reliability, and generic competition than on branded growth.
FAQs About Teflaro Patent and Market Outlook
Is Teflaro still sold in the United States?
Yes. Teflaro remains an FDA-approved intravenous ceftaroline fosamil product, although commercial availability and supplier status can change based on portfolio decisions and market supply.
Is ceftaroline the same as ceftaroline fosamil?
No. Ceftaroline fosamil is the prodrug administered intravenously. It is converted in the body to active ceftaroline.
Does Teflaro treat MRSA infections?
Yes. Teflaro is approved for selected bacterial infections involving susceptible pathogens, including MRSA in the approved clinical context.
Can a generic manufacturer substitute ceftaroline for Teflaro automatically?
Automatic substitution depends on FDA approval as therapeutically equivalent, state pharmacy law, institutional policy, and the product's approved dosage form and labeling.
Why has Teflaro not become a blockbuster antibiotic?
Its market is restricted by intravenous administration, hospital stewardship controls, established low-cost competitors, and the limited size of the advanced antibiotic segment.
References
- AbbVie Inc. (2021). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2020.
- Allergan plc. (2019). Annual report for the fiscal year ended December 31, 2018.
- Forest Laboratories, Inc. (2013). Annual report for the fiscal year ended March 31, 2013.
- Forest Laboratories, Inc. (2014). Annual report for the fiscal year ended March 31, 2014.
- U.S. Food and Drug Administration. (2010). Teflaro prescribing information.
- U.S. Food and Drug Administration. (2015). FDA approves Teflaro for pediatric patients.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
